NRG Therapeutics has received a grant from the nonprofit Target ALS to advance preclinical studies of its new class of oral small molecules targeting mitochondria, the energy producers of cells, as a potential treatment for amyotrophic lateral sclerosis (ALS). The 2024 In Vivo Target Validation grant program, an…
News
The U.S. Food and Drug Administration (FDA) has given the green light to Dr.Noah Biotech to initiate a Phase 1 clinical trial of NDC-011, a combination therapy for amyotrophic lateral sclerosis (ALS), in healthy volunteers. The trial, planned for the first half of 2025 at a single site…
AcuraStem has received $4 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance the development of AS-241, an investigational treatment strategy for amyotrophic lateral sclerosis (ALS) and related diseases. AS-241 is an antisense oligonucleotide (ASO), a type of small molecule that binds to RNA…
Measuring the levels of a novel protein biomarker called C-X-C motif chemokine ligand 12 — CXCL12 for short — in the spinal fluid may improve the diagnosis of amyotrophic lateral sclerosis (ALS) by better differentiating it from similar conditions, according to a new study. In particular, the…
A strategy that simultaneously targets motor neurons, astrocytes, and microglia — three cell types involved in the development and progression of amyotrophic lateral sclerosis (ALS) — was shown to further extend survival in a mouse model of the disease. Specifically, targeting the three cell types at the same time…
S-oxprenolol, an investigational therapy being developed by Actimed Therapeutics to treat muscle wasting in amyotrophic lateral sclerosis (ALS), has been granted orphan drug status in the U.S. That designation, awarded by the U.S. Food and Drug Administration, is given to therapies intended to treat rare diseases, like ALS, that…
A home-based multidisciplinary care model for people living with amyotrophic lateral sclerosis (ALS) was found feasible, and was rated as highly satisfactory by both patients and caregivers, according to a pilot study conducted in Germany. The care model also helped patients avoid hospitalizations and remain at home during the…
EverythingALS has launched a new version of its mobile app that now includes community support, artificial intelligence-powered chat assistance, and enhanced research opportunities to better serve people with amyotrophic lateral sclerosis (ALS) and their caregivers. The app, which was previously designed only for people taking part in observational…
Monepantel, a veterinary drug that PharmAust is repurposing for amyotrophic lateral sclerosis (ALS), continues to slow disease progression and extend survival when taken daily for up to nearly two years, while being generally well tolerated by patients. That’s according to interim results from an open-label extension…
Two U.S. representatives have introduced legislation that would establish a federally funded research program to study the link between environmental factors and amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research and Innovation in Neurological Science (Healthy…
Recent Posts
- New eye imaging approach may help distinguish ALS from Alzheimer’s
- After 15 years as an ALS caregiver, I’m still learning from others
- Early PrimeC use slows ALS progression, reduces complication risk
- Learning ALS self-advocacy involves being a little pushy
- Brain implant decodes finger moves so paralyzed patients can type